Omeprazole

also known as Prilosec · Losec · OMP · ABBOTT · Antra MUPS · Lansomeprazole · Lanzol · OME · +5 more

Other / unclassified targets CYP1A2, CYP2C19, FASN via inhibition

Developed for: gastroesophageal reflux disease · Helicobacter pylori infectious disease · dyspepsia · gastric ulcer · coronary artery disorder · Crohn disease · active peptic ulcer disease · breast cancer
+39 more
· castration-resistant prostate carcinoma · esophagitis · gastritis · NAFLD1 · peptic ulcer disease · Barrett esophagus · eosinophilic esophagitis · gastric cancer · lymphoma · peptic esophagitis · achlorhydria · chemotherapy-induced neuropathy · chronic rhinosinusitis · colorectal neoplasm · congenital dyserythropoietic anemia type 1 · COVID-19 · esophageal varices with bleeding · exocrine pancreatic carcinoma · fatty liver disease · gastric mucosa-associated lymphoid tissue lymphoma · gastric neoplasm · head and neck cancer · idiopathic pulmonary fibrosis · lung disorder · preneoplastic lesion · refractory malignant neoplasm · ulcer disease · upper respiratory tract disorder · Zollinger-Ellison syndrome · central serous chorioretinopathy · cystic fibrosis · digestive system disorder · duodenal ulcer · exocrine pancreatic insufficiency · food allergy · gastrin secretion abnormality · glaucoma · hemorrhagic disease · laryngeal disorder
Investigated by: AstraZeneca · Bristol-Myers Squibb · Boehringer Ingelheim · Eli Lilly and Company · GlaxoSmithKline · Jiangsu HengRui Medicine Co., Ltd.
+293 more
· POZEN · Pfizer · Sanofi · Janssen Research & Development, LLC · National Cancer Institute (NCI) · Merck Sharp & Dohme LLC · Amgen · Bayer · Celgene Corporation · Hoffmann-La Roche · Loxo Oncology, Inc. · Tehran University of Medical Sciences · Alexion Pharmaceuticals, Inc. · Bausch Health Americas, Inc. · Johnson & Johnson Pharmaceutical Research & Development, L.L.C. · Novartis Pharmaceuticals · AbbVie · Abbisko Therapeutics Co, Ltd · Acerta Pharma BV · Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · Ajou University School of Medicine · Assistance Publique - Hôpitaux de Paris · Astellas Pharma Europe B.V. · Beijing Children's Hospital · Biogen · Chinese University of Hong Kong · Cogentus Pharmaceuticals · Daiichi Sankyo · Dr. Reddy's Laboratories Limited · Emalex Biosciences Inc. · Genentech, Inc. · Gilead Sciences · Hadassah Medical Organization · Idorsia Pharmaceuticals Ltd. · Jules Desmeules · Medivation, Inc. · National Center for Complementary and Integrative Health (NCCIH) · National Institute of General Medical Sciences (NIGMS) · Nuventra, Inc. · Parexel · Procter and Gamble · Radboud University Medical Center · Shire · Takeda · Tanabe Pharma Corporation · Tanta University · The University of Texas Health Science Center, Houston · University Hospital, Basel, Switzerland · University Hospital, Geneva · University of Dundee · University of Michigan Rogel Cancer Center · ViiV Healthcare · Washington State University · Xspray Pharma AB · Abliva AB · Academy Military Medical Science, China · Academy of Finland · Achillion, a wholly owned subsidiary of Alexion · Agios Pharmaceuticals, Inc. · Ahon Pharmaceutical Co., Ltd. · Allist Pharmaceuticals, Inc. · Alnylam Pharmaceuticals · AnHeart Therapeutics Inc. · Aragon Pharmaceuticals, Inc. · Ardelyx · Assaf-Harofeh Medical Center · Assiut University · Atea Pharmaceuticals, Inc. · Autonomous University of Nuevo León · Avance Clinical Pty Ltd. · Axis Clinicals Limited · Aya Mohamed Sadek Elsaid · Ayman Magd Eldin Mohammad Sadek · Bausch & Lomb Incorporated · all 299 on the full record

Regulatory milestones approvals, filings & regulatory actions · 11 recorded

Milestone	Jurisdiction	Brand	Indication	Date	Sentence it was read from
Label expansions (10)	US (FDA)	PRILOSEC	—	1991-06-12 – 2016-02-03	fda.gov ↗
Approved	US (FDA)	PRILOSEC	—	1989-09-14	fda.gov ↗

Trials 342 · started per year

today

US approved 1989

19821983198419851986198719881989199019911992199319941995199619971998199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 09 trials
Phase 0	NCT06693960	Sep 2024 → Dec 2026 expected	—	Washington State University	Recruiting	No outcome recorded
Phase 0	NCT06378398	Jun 2024 → Feb 2026	colorectal neoplasm	University of Michigan Rogel Cancer Center	Completed	No outcome recorded
Phase 0	NCT05891119	Jun 2023 → Aug 2024	atopic eczema	Amgen	Completed	No outcome recorded
Phase 0	NCT04930991	Sep 2021 → Mar 2026	exocrine pancreatic carcinoma	University of Oklahoma	Terminated	No outcome recorded
Phase 0	NCT05005910	Sep 2021 → Dec 2022	peptic ulcer disease	Uayporn Kaosombatwattana	Completed	No outcome recorded
Phase 0	NCT04170270	Nov 2019 → Dec 2020	active peptic ulcer disease	Assiut University	Unknown	No outcome recorded
Phase 0	NCT04525664	Oct 2018 → May 2019	Helicobacter pylori infectious disease, dyspepsia	Washington University School of Medicine	Completed	No outcome recorded
Phase 0	NCT02844621	May → Dec 2016	—	The University of Texas Health Science Center at San Antonio	Completed	No outcome recorded
Phase 0	NCT01824199	Mar 2013 → Nov 2016	esophagitis	Mayo Clinic	Withdrawn	No outcome recorded
Phase 1203 trials
Phase 1	NCT07700953	Jul → Aug 2026 overdue	—	Abbisko Therapeutics Co, Ltd	Not yet recruiting	No outcome recorded
Phase 1	NCT07665723	Jun 2026 → Jul 2027 expected	ulcerative colitis	Hoffmann-La Roche	Recruiting	No outcome recorded
Phase 1	NCT07565441	May → Nov 2026 expected	autosomal dominant polycystic kidney disease	Jemincare	Not yet recruiting	No outcome recorded
Phase 1	NCT07426042	Apr → May 2026 overdue	—	Min Kyu Park	Not yet recruiting	No outcome recorded
Phase 1	NCT07214662	Jan 2026 → Jun 2030 expected	breast cancer	Genentech, Inc.	Recruiting	No outcome recorded
Phase 1	NCT07223671	Dec 2025 → Feb 2026	—	Bristol-Myers Squibb	Completed	No outcome recorded
Phase 1	NCT07269756	Dec 2025 → Mar 2026	obesity disorder	Shandong Suncadia Medicine Co., Ltd.	Completed	No outcome recorded
Phase 1	NCT07259330	Oct 2025 → Mar 2026	—	SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany	Completed	No outcome recorded
Phase 1	NCT07235748	Oct → Dec 2025	—	Servier	Completed	No outcome recorded
Phase 1	NCT07149415	Sep → Oct 2025	—	Biogen	Completed	No outcome recorded
Show all 203 trials opens the full record — a long page
Phase 1/23 trials
Phase 1/2	NCT02892357	Jan 2017 → Sep 2019	gastroesophageal reflux disease	Xiyuan Hospital of China Academy of Chinese Medical Sciences	Unknown	No outcome recorded
Phase 1/2	NCT01109381	May 2010 → Dec 2011	Helicobacter pylori infectious disease	Synergy Pharmaceuticals Pte. Ltd.	Terminated	No outcome recorded
Phase 1/2	NCT01086722	Feb 2010 → Feb 2013	morbid obesity	Hospital del Mar Medical Research Institute (IMIM)	Completed	No outcome recorded
Phase 219 trials
Phase 2	NCT06510010	Dec 2024 → Dec 2026 expected	chemotherapy-induced toxicity	Sixth Affiliated Hospital, Sun Yat-sen University	Recruiting	No outcome recorded
Phase 2	NCT06861478	Oct 2024 → Aug 2026 overdue	—	Autonomous University of Nuevo León	Recruiting	No outcome recorded
Phase 2	NCT04562116	Dec 2021 → Jun 2023	atopic eczema	Galderma R&D	Completed	No outcome recorded
Phase 2	NCT04337580	Mar 2021 → Feb 2028 expected	castration-resistant prostate carcinoma, refractory malignant neoplasm	Wake Forest University Health Sciences	Recruiting	No outcome recorded
Phase 2	NCT03428568	Mar 2018 → Mar 2019	dyspepsia, gastritis	King Abdullah International Medical Research Center	Unknown	No outcome recorded
Phase 2	NCT02595372	Nov 2015 → Nov 2019	breast cancer	Kathy Miller	Completed	No outcome recorded
Phase 2	NCT02085018	Mar 2014 → Sep 2016	idiopathic pulmonary fibrosis	Newcastle-upon-Tyne Hospitals NHS Trust	Completed	No outcome recorded
Phase 2	NCT02013453	Dec 2013 → Dec 2016	head and neck cancer	University of Michigan Rogel Cancer Center	Withdrawn	No outcome recorded
Phase 2	NCT01712711	Sep 2012 → Feb 2013	NAFLD1	Tehran University of Medical Sciences	Completed	No outcome recorded
Phase 2	NCT01876108	Jul 2012 → Jul 2013	fatty liver disease	Tehran University of Medical Sciences	Completed	No outcome recorded
Phase 2	NCT01654549	Apr → Sep 2012	NAFLD1	Tehran University of Medical Sciences	Completed	No outcome recorded
Phase 2	NCT01759628	Apr 2012 → Jun 2013	NAFLD1	Tehran University of Medical Sciences	Completed	No outcome recorded
Phase 2	NCT01136317	Apr → Jul 2010	gastroesophageal reflux disease	Nantes University Hospital	Completed	No outcome recorded
Phase 2	NCT01657578	Jun 2007 → Dec 2010	gastroesophageal reflux disease	Assistance Publique - Hôpitaux de Paris	Completed	No outcome recorded
Phase 2	NCT00426595	Apr → Nov 2007	gastroesophageal reflux disease	University Hospital, Ghent	Completed	No outcome recorded
Phase 2	NCT02518373	Apr 2000 → Feb 2001	colorectal cancer	Cancer Advances Inc.	Completed	No outcome recorded
Phase 2	NCT00003151	Sep 1997 → Oct 1998	lymphoma	European Organisation for Research and Treatment of Cancer - EORTC	Completed	No outcome recorded
Phase 2	NCT00002682	Aug 1995 → Oct 2001	lymphoma	M.D. Anderson Cancer Center	Completed	No outcome recorded
Phase 2	NCT00001191	Feb 1983 → Dec 2007	Zollinger-Ellison syndrome, gastrin-producing neuroendocrine tumor	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	Completed	No outcome recorded

Phase 2/31 trial
Phase 2/3	NCT02004197	Jan 2010 → Sep 2012	Helicobacter pylori infectious disease	Hafiz Muhammad Asif	Completed	No outcome recorded
Phase 332 trials
Phase 3	NCT07104318	Jul 2026 → Jun 2029 expected	Helicobacter pylori infectious disease	VA Office of Research and Development	Not yet recruiting	No outcome recorded
Phase 3	NCT06393868	Nov 2024 → Dec 2027 expected	thrombotic disease, venous thromboembolism	Ottawa Hospital Research Institute	Recruiting	No outcome recorded
Phase 3	NCT05646862	Jun 2023 → Nov 2026 expected	breast cancer	Hoffmann-La Roche	Active not recruiting	No outcome recorded
Phase 3	NCT05680870	Feb 2023 → Dec 2024	chemotherapy-induced neuropathy	Aya Mohamed Sadek Elsaid	Completed	No outcome recorded
Phase 3	NCT02422706	Jan 2015 → Dec 2018	gastritis	Tanta University	Unknown	No outcome recorded
Phase 3	NCT02621359	Jan 2015 → Dec 2022	dyspepsia	Tanta University	Unknown	No outcome recorded
Phase 3	NCT01980095	Nov 2013 → Jun 2015	Helicobacter pylori infectious disease, dyspepsia	RedHill Biopharma Limited	Completed	No outcome recorded
Phase 3	NCT01661101	Jan 2013 → Mar 2018	myocardial disorder	Population Health Research Institute	Completed	No outcome recorded
Phase 3	NCT01462318	Nov 2011 → Jan 2016	relapsing-remitting multiple sclerosis	Biogen	Completed	No outcome recorded
Phase 3	NCT01499368	Nov 2011 → Nov 2012	esophagitis	Boryung Pharmaceutical Co., Ltd	Completed	No outcome recorded
Phase 3	NCT01493089	Apr → Oct 2011	gastroesophageal reflux disease	Norgine	Completed	No outcome recorded
Phase 3	NCT00961350	Oct 2009 → Feb 2012	gastric ulcer	POZEN	Completed	No outcome recorded
Phase 3	NCT00995410	Oct 2009 → May 2011	peptic ulcer disease	POZEN	Completed	No outcome recorded
Phase 3	NCT00960869	Oct 2009 → Feb 2012	gastric ulcer	POZEN	Completed	No outcome recorded
Phase 3	NCT01005719	Sep 2009 → Jan 2010	—	Bayer	Completed	No outcome recorded
Phase 3	NCT00971581	Aug 2009 → May 2010	—	Sanofi	Completed	No outcome recorded
Phase 3	NCT00664209	Jan 2008 → Jun 2011	Helicobacter pylori infectious disease, Parkinson disease	University of California, Los Angeles	Terminated	No outcome recorded
Phase 3	NCT00634114	Jan 2008 → May 2009	esophagitis	AstraZeneca	Completed	No outcome recorded
Phase 3	NCT00557921	Dec 2007 → Nov 2009	acute coronary syndrome, coronary artery disorder, myocardial infarction	Cogentus Pharmaceuticals	Terminated	No outcome recorded
Phase 3	NCT00633932	Dec 2007 → Dec 2008	peptic esophagitis	AstraZeneca	Completed	No outcome recorded
Phase 3	NCT00367211	Sep 2006 → Sep 2007	ankylosing spondylitis, osteoarthritis	POZEN	Completed	No outcome recorded
Phase 3	NCT00668317	Sep 2006 → Sep 2009	—	Hull University Teaching Hospitals NHS Trust	Terminated	No outcome recorded
Phase 3	NCT00402259	Aug 2006 → Oct 2007	—	AstraZeneca	Completed	No outcome recorded
Phase 3	NCT00719420	Apr 2006 → Feb 2007	Helicobacter pylori infectious disease	University of North Texas Health Science Center	Completed	No outcome recorded
Phase 3	NCT00374101	Jan 2005 → Mar 2007	active peptic ulcer disease	Casa Sollievo della Sofferenza IRCCS	Completed	No outcome recorded
Phase 3	NCT00259051	Jan → Aug 2004	gastroesophageal reflux disease	AstraZeneca	Completed	No outcome recorded
Phase 3	NCT00259077	Oct 2003 → Jul 2004	gastroesophageal reflux disease	AstraZeneca	Completed	No outcome recorded
Phase 3	NCT00164931	Oct 2003 → ?	active peptic ulcer disease	Chinese University of Hong Kong	Completed	No outcome recorded
Phase 3	NCT00045799	May 2002 → May 2003	—	Bausch Health Americas, Inc.	Completed	No outcome recorded
Phase 3	NCT00256737	Jan 1998 → Oct 2005	gastroesophageal reflux disease	AstraZeneca	Completed	No outcome recorded
Phase 3	NCT00339768	Jul 1995 → Jun 1996	preneoplastic lesion	National Cancer Institute (NCI)	Completed	No outcome recorded
Phase 3	NCT00003617	Mar 1995 → ?	gastric cancer	Lymphoma Trials Office	Unknown	No outcome recorded

Phase 449 trials
Phase 4	NCT07611162	May 2026 → May 2030 expected	gastroesophageal reflux disease	University of Mons	Not yet recruiting	No outcome recorded
Phase 4	NCT07040839	Jul 2025 → Feb 2026 overdue	Helicobacter pylori infectious disease	Rehman Medical Institute - RMI	Not yet recruiting	No outcome recorded
Phase 4	NCT06690164	Jun → Dec 2025 overdue	—	National University Hospital, Singapore	Recruiting	No outcome recorded
Phase 4	NCT05624229	Oct 2023 → Dec 2025 overdue	esophageal varices with bleeding	West China Hospital	Not yet recruiting	No outcome recorded
Phase 4	NCT05799105	Mar 2023 → Mar 2027 expected	ulcer disease	Stephen Firkins	Recruiting	No outcome recorded
Phase 4	NCT06050824	Jul 2022 → Jul 2023	Helicobacter pylori infectious disease	Helwan University	Completed	No outcome recorded
Phase 4	NCT04149470	Oct 2020 → Aug 2024 overdue	eosinophilic esophagitis	University of Colorado, Denver	Active not recruiting	No outcome recorded
Phase 4	NCT03781596	Oct 2018 → Oct 2020	eosinophilic esophagitis	Claire Daniels	Unknown	No outcome recorded
Phase 4	NCT04039412	Jun → Dec 2018	Helicobacter pylori infectious disease	Ayman Magd Eldin Mohammad Sadek	Completed	No outcome recorded
Phase 4	NCT03347513	Nov 2017 → Mar 2019	Helicobacter pylori infectious disease, iron deficiency anemia, pregnancy disorder	Kasr El Aini Hospital	Unknown	No outcome recorded
Phase 4	NCT02760615	Nov 2016 → Aug 2020	Crohn disease, ulcerative colitis	Takeda	Withdrawn	No outcome recorded
Phase 4	NCT02794844	Jul 2016 → Jan 2017	gastroesophageal reflux disease	Nemours Children's Clinic	Completed	No outcome recorded
Phase 4	NCT02586636	Mar 2016 → Apr 2018	—	NHS Tayside	Completed	No outcome recorded
Phase 4	NCT02730026	Jun 2015 → Dec 2016	—	Luis Fernando Simoneti	Completed	No outcome recorded
Phase 4	NCT02291666	Apr 2015 → Jul 2019	type 2 diabetes mellitus	University of Montreal Hospital Centre (CHUM)	Completed	No outcome recorded
Phase 4	NCT02394340	Feb → Apr 2015	dermatophytosis of groin and perianal area, tinea pedis	Bausch & Lomb Incorporated	Completed	No outcome recorded
Phase 4	NCT03378960	Oct 2014 → Dec 2015	—	Emilio Vargas Castrillón	Completed	No outcome recorded
Phase 4	NCT02623816	Aug 2014 → Dec 2015	dyspepsia	MetroHealth Medical Center	Completed	No outcome recorded
Phase 4	NCT02635191	Mar 2014 → Mar 2016	Helicobacter pylori infectious disease	Beijing Children's Hospital	Unknown	No outcome recorded
Phase 4	NCT02140073	Dec 2013 → Jun 2014	gastroesophageal reflux disease	Belarusian Medical Academy of Post-Graduate Education	Unknown	No outcome recorded
Phase 4	NCT01938534	Sep 2013 → Dec 2014	—	Ajou University School of Medicine	Unknown	No outcome recorded
Phase 4	NCT01901276	Aug 2013 → Mar 2015	Clostridium difficile colitis	Daniel Freedberg, MD	Completed	No outcome recorded
Phase 4	NCT01795794	Apr → Dec 2013	congenital dyserythropoietic anemia type 1	Soroka University Medical Center	Unknown	No outcome recorded
Phase 4	NCT02395458	Mar 2013 → Feb 2015	Helicobacter pylori infectious disease	Coordinación de Investigación en Salud, Mexico	Completed	No outcome recorded
Phase 4	NCT02685436	Mar 2013 → May 2015	gastroesophageal reflux disease	Mansoura University Children Hospital	Completed	No outcome recorded
Phase 4	NCT01766050	Jan → Apr 2013	transplant rejection	Bristol-Myers Squibb	Completed	No outcome recorded
Phase 4	NCT02922699	Jan → Jun 2013	gastroesophageal reflux disease	Dr. Reddy's Laboratories Limited	Completed	No outcome recorded
Phase 4	NCT03146325	Nov 2012 → Jun 2016	Helicobacter pylori infectious disease	The University of Texas Health Science Center, Houston	Withdrawn	No outcome recorded
Phase 4	NCT01735227	Nov 2012 → Oct 2013	acute coronary syndrome	Yaling Han	Unknown	No outcome recorded
Phase 4	NCT03650543	Sep 2012 → Aug 2015	Helicobacter pylori infectious disease	Javeriana University	Completed	No outcome recorded
Phase 4	NCT02703896	Jan 2012	lung disorder	King Saud University	Completed	No outcome recorded
Phase 4	NCT01587885	Jan → Apr 2012	dyspepsia	Bayer	Completed	No outcome recorded
Phase 4	NCT01896557	Oct 2011 → Jun 2013	coronary artery disorder	University of Sao Paulo General Hospital	Completed	No outcome recorded
Phase 4	NCT01464060	Sep 2011 → Dec 2012	Helicobacter pylori infectious disease	Infante, Javier Molina, M.D.	Unknown	No outcome recorded
Phase 4	NCT01335334	Mar → Jun 2011	Helicobacter pylori infectious disease	The University of Texas Health Science Center, Houston	Unknown	No outcome recorded
Phase 4	NCT01273441	Dec 2010 → Jun 2012	Helicobacter pylori infectious disease	Fundación de Investigación Biomédica - Hospital Universitario de La Princesa	Completed	No outcome recorded
Phase 4	NCT03086070	Jan → Apr 2010	chronic rhinosinusitis, gastroesophageal reflux disease	Children's Hospital Srebrnjak	Completed	No outcome recorded
Phase 4	NCT00950339	Aug 2009 → Jun 2011	coronary artery disorder	Tel-Aviv Sourasky Medical Center	Completed	No outcome recorded
Phase 4	NCT00930670	Jun 2009 → Dec 2011	coronary artery disorder	Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec	Completed	No outcome recorded
Phase 4	NCT00903448	Apr → Jun 2009	—	Procter and Gamble	Completed	No outcome recorded
Phase 4	NCT00861640	Mar 2009 → Mar 2010	—	Kaohsiung Medical University Chung-Ho Memorial Hospital	Unknown	No outcome recorded
Phase 4	NCT00808769	Nov → Dec 2008	—	Procter and Gamble	Completed	No outcome recorded
Phase 4	NCT00582972	Jan → Dec 2008	achlorhydria, gastroesophageal reflux disease, osteoporosis	University of Wisconsin, Madison	Completed	No outcome recorded
Phase 4	NCT00492622	Jun 2007 → Dec 2008	gastroesophageal reflux disease, gastroparesis	University of Louisville	Completed	No outcome recorded
Phase 4	NCT00251030	Nov 2005 → Jan 2006	—	Pfizer	Completed	No outcome recorded
Phase 4	NCT00164866	Feb 2004 → Sep 2005	peptic ulcer disease	Chinese University of Hong Kong	Completed	No outcome recorded
Phase 4	NCT00641264	May 2001 → Jun 2003	gastroesophageal reflux disease	AstraZeneca	Completed	No outcome recorded
Phase 4	NCT02123498	? → May 2015	eustachian tube disorder, gastroesophageal reflux disease	Loma Linda University	Withdrawn	No outcome recorded
Phase 4	NCT00475527	—	Helicobacter pylori infectious disease, iron deficiency anemia	Hadassah Medical Organization	Withdrawn	No outcome recorded

Phase not applicable26 trials
—	NCT06943794	Mar 2026 → May 2030 expected	gastric cancer	Fudan University	Not yet recruiting	No outcome recorded
—	NCT06917963	Apr 2025 → Jun 2027 expected	colon carcinoma, ileus, inflammatory bowel disease	Medical University of Gdansk	Recruiting	No outcome recorded
—	NCT05741385	Oct 2023 → Aug 2024	cirrhosis of liver	Boehringer Ingelheim	Completed	No outcome recorded
—	NCT04394663	Oct 2020 → May 2025 overdue	—	King Chulalongkorn Memorial Hospital	Recruiting	No outcome recorded
—	NCT04333407	Apr 2020 → Nov 2021	COVID-19	Imperial College London	Terminated	No outcome recorded
—	NCT03337945	Apr 2018 → Jun 2021	cirrhosis of liver	University Hospital, Basel, Switzerland	Completed	No outcome recorded
—	NCT03365609	Sep 2017 → Oct 2025 overdue	Helicobacter pylori infectious disease	Ying HUANG	Recruiting	No outcome recorded
—	NCT02689583	Mar 2016 → Mar 2017	gastric ulcer, gastritis	First Affiliated Hospital of Zhejiang University	Unknown	No outcome recorded
—	NCT02590185	Dec 2015 → Dec 2019	major depressive disorder	Assistance Publique - Hôpitaux de Paris	Unknown	No outcome recorded
—	NCT02789527	Nov 2015 → Apr 2017	—	Estella S. Poloni	Completed	No outcome recorded
—	NCT02788591	Aug 2015 → Jun 2021	gastroesophageal reflux disease	LCMC Health	Terminated	No outcome recorded
—	NCT02893709	Jun 2015 → Jul 2016	gastroesophageal reflux disease	Changi General Hospital	Completed	No outcome recorded
—	NCT02438072	Dec 2014 → Dec 2015	depressive disorder	University Hospital, Geneva	Unknown	No outcome recorded
—	NCT02016820	Nov 2014 → Jan 2017	Clostridium difficile colitis	Columbia University	Terminated	No outcome recorded
—	NCT01723059	Feb 2012 → Jan 2013	Helicobacter pylori infectious disease	Dallas VA Medical Center	Unknown	No outcome recorded
—	NCT03563287	Jan 2012 → Dec 2014	morbid obesity	University of Eastern Finland	Completed	No outcome recorded
—	NCT01458990	Oct 2011 → Feb 2018	cirrhosis of liver	Hunter Holmes Mcguire Veteran Affairs Medical Center	Completed	No outcome recorded
—	NCT01361217	Sep 2011 → Jun 2012	—	University of Washington	Completed	No outcome recorded
—	NCT01341600	Jul 2010 → May 2011	—	University of Maryland, Baltimore	Completed	No outcome recorded
—	NCT01133951	Jun 2010 → Jan 2012 overdue	Helicobacter pylori infectious disease, gastric neoplasm	Jie-Jun Wang	Active not recruiting	No outcome recorded
—	NCT01122160	May → Dec 2010	—	USDA Beltsville Human Nutrition Research Center	Completed	No outcome recorded
—	NCT01129778	Nov 2009 → Jul 2010	Barrett esophagus, gastroesophageal reflux disease	Stanford University	Terminated	No outcome recorded
—	NCT01061034	Mar → Jun 2007	—	Assaf-Harofeh Medical Center	Completed	No outcome recorded
—	NCT00327132	Jul 2006 → Dec 2015	gastric mucosa-associated lymphoid tissue lymphoma	National Health Research Institutes, Taiwan	Completed	No outcome recorded
—	NCT04154748	Jun 2002 → Feb 2015	Barrett esophagus	Maria Sklodowska-Curie National Research Institute of Oncology	Completed	No outcome recorded
—	NCT02039869	? → Dec 2015	dyspepsia, gastroesophageal reflux disease	Virginia Commonwealth University	Withdrawn	No outcome recorded

Also used as a comparator or background therapy in 157 trials

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 02 trials
Phase 0	NCT03105375 Comparator	Feb → Oct 2017	—	Cinclus Pharma Holding AB	Completed	No outcome recorded
Phase 0	NCT01465113 Background	May 2010 → Feb 2016	Barrett esophagus	Case Comprehensive Cancer Center	Completed	No outcome recorded
Phase 123 trials
Phase 1	NCT07156201 Background	Aug 2025 → Mar 2026 overdue	—	Actio Biosciences, Inc.	Recruiting	No outcome recorded
Phase 1	NCT04199624 Background	Oct 2021 → Jun 2023	achlorhydria	Indiana University	Completed	No outcome recorded
Phase 1	NCT03100838 Comparator	Mar → Dec 2017	—	Food and Drug Administration (FDA)	Completed	No outcome recorded
Phase 1	NCT02950259 Background	Feb 2017 → May 2019	triple-negative breast carcinoma	Providence Health & Services	Completed	No outcome recorded
Phase 1	NCT03033342 Background	Aug 2016 → Feb 2017	—	MicuRx	Completed	No outcome recorded
Phase 1	NCT02684799 Comparator	Jan → Apr 2016	—	Tobira Therapeutics, Inc.	Completed	No outcome recorded
Phase 1	NCT02365558 Background	Jan → Apr 2015	—	Eli Lilly and Company	Completed	No outcome recorded
Phase 1	NCT02229877 Background	Oct 2014 → May 2015	—	Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)	Completed	No outcome recorded
Phase 1	NCT01822977 Comparator	Mar → Dec 2013	Clostridium difficile colitis	Mayo Clinic	Completed	No outcome recorded
Phase 1	NCT02249936 Background	Feb 2013	—	Ardelyx	Completed	No outcome recorded
Phase 1	NCT01782560 Comparator	Feb 2013 → Jul 2015	laryngeal disorder	Children's & Women's Health Centre of British Columbia	Withdrawn	No outcome recorded
Phase 1	NCT01694706 Comparator	Sep → Dec 2012	—	Boehringer Ingelheim	Completed	No outcome recorded
Phase 1	NCT01570569 Comparator	Jan → Mar 2011	—	Inje University	Completed	No outcome recorded
Phase 1	NCT01557335 Comparator	Nov 2010 → Feb 2011	platelet aggregation, spontaneous	POZEN	Completed	No outcome recorded
Phase 1	NCT01710995 Comparator	Oct → Nov 2010	gastroesophageal reflux disease	Norgine	Completed	No outcome recorded
Phase 1	NCT01187862 Background	Jul 2010 → Feb 2011	—	University Hospital, Basel, Switzerland	Completed	No outcome recorded
Phase 1	NCT01415128 Comparator	Apr → May 2010	erectile dysfunction	VIVUS LLC	Completed	No outcome recorded
Phase 1	NCT01170533 Comparator	Mar 2009 → Aug 2010	—	University of Florida	Completed	No outcome recorded
Phase 1	NCT00818870 Comparator	Dec 2008 → Jun 2009	gastroesophageal reflux disease	Vecta Ltd.	Completed	No outcome recorded
Phase 1	NCT01042704 Background	Feb 2008 → Jan 2011	plasma cell myeloma	Robert Redner, MD	Completed	No outcome recorded
Phase 1	NCT00632086 Background	Feb 2008	—	POZEN	Completed	No outcome recorded
Phase 1	NCT00692510 Background	Nov 2007 → Sep 2008	Alzheimer disease	AstraZeneca	Completed	No outcome recorded
Phase 1	NCT01000220 Comparator	—	glaucoma	Shahid Beheshti University of Medical Sciences	Unknown	No outcome recorded

Phase 1/28 trials
Phase 1/2	NCT03167398 Background	Feb 2018 → Dec 2019	—	Rambam Health Care Campus	Completed	No outcome recorded
Phase 1/2	NCT02272868 Background	Jan 2015 → Oct 2016	Crohn disease	Seattle Children's Hospital	Terminated	No outcome recorded
Phase 1/2	NCT02504554 Background	Jul 2014 → Apr 2016	autism spectrum disorder, digestive system disorder	Arizona State University	Completed	No outcome recorded
Phase 1/2	NCT02803216 Background	Jan 2013 → Dec 2015	Helicobacter pylori infectious disease	Xiyuan Hospital of China Academy of Chinese Medical Sciences	Completed	No outcome recorded
Phase 1/2	NCT01287195 Background	Apr 2011 → May 2013	ulcerative colitis	Brigham and Women's Hospital	Completed	No outcome recorded
Phase 1/2	NCT01129713 Comparator	May 2010 → May 2015	dyspepsia, gastroesophageal reflux disease	Effexus Pharmaceutical	Unknown	No outcome recorded
Phase 1/2	NCT01146197 Background	Feb 2010 → Dec 2012	Gitelman syndrome	Assistance Publique - Hôpitaux de Paris	Completed	No outcome recorded
Phase 1/2	NCT00817245 Comparator	Mar → Oct 2008	central serous chorioretinopathy	Tabriz University	Completed	No outcome recorded

Phase 221 trials
Phase 2	NCT07293910 Comparator	Feb → Dec 2026 expected	Helicobacter pylori infectious disease	Tanta University	Recruiting	No outcome recorded
Phase 2	NCT06150898 Background	May 2025 → Apr 2027 expected	estrogen-receptor positive breast cancer	Jules Bordet Institute	Recruiting	No outcome recorded
Phase 2	NCT06539494 Comparator	Jul 2024 → Jan 2026 overdue	metabolic dysfunction-associated steatotic liver disease	Academic Medical Center - University of Amsterdam	Recruiting	No outcome recorded
Phase 2	NCT06973889 Background	Dec 2023 → Dec 2024	Helicobacter pylori infectious disease, digestive system disorder	Mashhad University of Medical Sciences	Completed	No outcome recorded
Phase 2	NCT04672018 Comparator	Nov 2022 → Feb 2023	gastritis	University of Karachi	Completed	No outcome recorded
Phase 2	NCT03551691 Comparator	Aug 2018 → Nov 2022	cystic fibrosis, exocrine pancreatic insufficiency	Children's Hospital of Philadelphia	Completed	No outcome recorded
Phase 2	NCT03968302 Background	Jun 2018 → May 2019	Helicobacter pylori infectious disease	Ziauddin University	Completed	No outcome recorded
Phase 2	NCT03291249 Background	Dec 2017 → Dec 2018	metabolic dysfunction-associated steatohepatitis, type 2 diabetes mellitus	Tiziana Life Sciences LTD	Withdrawn	No outcome recorded
Phase 2	NCT03267680 Background	Nov 2017 → Aug 2023	uterine cervix carcinoma in situ, vulvar intraepithelial neoplasia	University of Southern California	Terminated	No outcome recorded
Phase 2	NCT02637557 Background	Mar 2016 → Apr 2017	gastroesophageal reflux disease	Ironwood Pharmaceuticals, Inc.	Completed	No outcome recorded
Phase 2	NCT02472600 Comparator	Feb 2016 → Nov 2017	—	Stephen Harbarth	Unknown	No outcome recorded
Phase 2	NCT02609386 Background	Jan 2016 → Feb 2022	oral cavity squamous cell carcinoma	Brooklyn ImmunoTherapeutics, LLC	Completed	No outcome recorded
Phase 2	NCT01408849 Comparator	Feb 2015 → Jan 2016	dyspepsia	Casa Espirita Terra de Ismael	Terminated	No outcome recorded
Phase 2	NCT02288078 Comparator	Oct 2014 → Sep 2015	rectal cancer	Clinical Research Support Center Kyush	Unknown	No outcome recorded
Phase 2	NCT03362268 Comparator	Feb → Jun 2014	peptic ulcer disease	Livzon Pharmaceutical Group Inc.	Completed	No outcome recorded
Phase 2	NCT01678053 Background	Sep 2012 → Jan 2015	laryngeal granuloma	Phillip Song, MD	Withdrawn	No outcome recorded
Phase 2	NCT00978016 Background	Sep 2009 → Dec 2010	gastroesophageal reflux disease	XenoPort, Inc.	Completed	No outcome recorded
Phase 2	NCT00210470 Background	Jul 2005 → Dec 2010	head and neck squamous cell carcinoma	Brooklyn ImmunoTherapeutics, LLC	Completed	No outcome recorded
Phase 2	NCT00953381 Comparator	Oct 2004 → Mar 2005	duodenal ulcer	Livzon Pharmaceutical Group Inc.	Completed	No outcome recorded
Phase 2	NCT01002443 Comparator	Jul 2003 → Mar 2006	gastric cancer	National Cancer Center, Korea	Completed	No outcome recorded
Phase 2	NCT00001337 Background	May 1993 → May 2024	Burkitt lymphoma, anaplastic large cell lymphoma, mediastinal gray zone lymphoma, primary mediastinal large B-cell lymphoma	National Cancer Institute (NCI)	Completed	No outcome recorded

Phase 2/32 trials
Phase 2/3	NCT06719622 Comparator	Jul 2024 → Dec 2027 expected	Crohn disease	Medical University of Warsaw	Enrolling by invitation	No outcome recorded
Phase 2/3	NCT01269788 Comparator	Aug 2010 → Aug 2011	gastroesophageal reflux disease	Tehran University of Medical Sciences	Completed	No outcome recorded
Phase 330 trials
Phase 3	NCT07275827 Comparator	Feb → Apr 2026 overdue	Helicobacter pylori infectious disease	Tanta University	Not yet recruiting	No outcome recorded
Phase 3	NCT04069286 Comparator	Mar 2025 → Jul 2026 overdue	dyspepsia	Infan Industria Quimica Farmaceutica Nacional	Not yet recruiting	No outcome recorded
Phase 3	NCT07487142 Comparator	Jun 2024 → Dec 2025	Helicobacter pylori infectious disease	Beni-Suef University	Completed	No outcome recorded
Phase 3	NCT05863858 Comparator	Jun 2020 → Dec 2021	Helicobacter pylori infectious disease	Iyad Naeem Muhammad, PhD	Completed	No outcome recorded
Phase 3	NCT03662269 Background	Oct 2018 → Aug 2020	respiratory system disorder	The First Affiliated Hospital of Guangzhou Medical University	Unknown	No outcome recorded
Phase 3	NCT03367195 Comparator	Aug 2018 → May 2020	gastroesophageal reflux disease	Dexa Medica Group	Terminated	No outcome recorded
Phase 3	NCT03491995 Background	Apr 2018 → Apr 2023	Helicobacter pylori infectious disease	Tanta University	Unknown	No outcome recorded
Phase 3	NCT03205228 Comparator	Jul 2017 → Jun 2018	—	Mahidol University	Completed	No outcome recorded
Phase 3	NCT03198507 Background	Jun 2017 → Oct 2018	Helicobacter pylori infectious disease, dyspepsia	RedHill Biopharma Limited	Completed	No outcome recorded
Phase 3	NCT01762644 Comparator	Aug 2015 → May 2016	type 1 diabetes mellitus	Perle Bioscience, Inc.	Withdrawn	No outcome recorded
Phase 3	NCT03362281 Comparator	Oct 2014 → Apr 2015	active peptic ulcer disease	Livzon Pharmaceutical Group Inc.	Completed	No outcome recorded
Phase 3	NCT02262169 Comparator	Oct 2014 → Feb 2019	peptic ulcer disease	Dexa Medica Group	Terminated	No outcome recorded
Phase 3	NCT01566474 Comparator	Apr 2012 → Jun 2017	Barrett esophagus	Aragon Institute of Health Sciences	Completed	No outcome recorded
Phase 3	NCT01150162 Comparator	Oct 2010 → Jun 2012	gastric ulcer	Otsuka Pakistan Limited	Completed	No outcome recorded
Phase 3	NCT01338077 Comparator	Oct 2010 → Jan 2012	dyspepsia, gastroesophageal reflux disease	Chang Gung Memorial Hospital	Completed	No outcome recorded
Phase 3	NCT00857597 Comparator	Mar 2009 → Dec 2011	gastroesophageal reflux disease	University of Pittsburgh	Terminated	No outcome recorded
Phase 3	NCT01077076 Comparator	Dec 2008 → Mar 2009	gastrin secretion abnormality	Bayer	Completed	No outcome recorded
Phase 3	NCT00712413 Background	Aug → Dec 2008	Helicobacter pylori infectious disease	Forest Laboratories	Withdrawn	No outcome recorded
Phase 3	NCT00669955 Comparator	Jun 2008 → Jul 2009	Helicobacter pylori infectious disease	Forest Laboratories	Completed	No outcome recorded
Phase 3	NCT00765206 Comparator	May → Aug 2008	—	Bayer	Completed	No outcome recorded
Phase 3	NCT00674115 Comparator	Apr → Jun 2008	—	Bayer	Completed	No outcome recorded
Phase 3	NCT00559364 Background	Nov 2007 → Jul 2009	chronic pancreatitis, exocrine pancreatic insufficiency	Forest Laboratories	Completed	No outcome recorded
Phase 3	NCT00542347 Comparator	Sep 2007 → Apr 2017	achlorhydria	Queen's University	Terminated	No outcome recorded
Phase 3	NCT00404534 Background	Oct 2006 → Jun 2009	dyspepsia	Hospital de Clinicas de Porto Alegre	Completed	No outcome recorded
Phase 3	NCT00290823 Background	Apr 2006 → Mar 2011	cysticercosis	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 3	NCT00952978 Comparator	Sep 2005 → Feb 2006	duodenal ulcer	Livzon Pharmaceutical Group Inc.	Completed	No outcome recorded
Phase 3	NCT00226044 Comparator	Sep 2005 → Sep 2016	congenital diaphragmatic hernia, esophageal atresia, gastroesophageal reflux disease	Rijnstate Hospital	Completed	No outcome recorded
Phase 3	NCT01510730 Comparator	Jan 2005 → Feb 2011	Helicobacter pylori infectious disease, gastric neoplasm	Seoul National University Hospital	Completed	No outcome recorded
Phase 3	NCT00519519 Comparator	Jul 2004 → Oct 2007	peptic ulcer disease	Singapore General Hospital	Completed	No outcome recorded
Phase 3	NCT02407119 Comparator	Jun 2003 → Jun 2016 overdue	Helicobacter pylori infectious disease, gastric carcinoma	National Cancer Center, Korea	Active not recruiting	No outcome recorded

Phase 448 trials
Phase 4	NCT07021729 Comparator	Dec 2025 → Mar 2026 overdue	Helicobacter pylori infectious disease	Rehman Medical Institute - RMI	Not yet recruiting	No outcome recorded
Phase 4	NCT06255886 Comparator	Oct 2025 → Dec 2026 expected	gastroesophageal reflux disease	Odense University Hospital	Recruiting	No outcome recorded
Phase 4	NCT06943482 Comparator	Jul 2025 → Feb 2028 expected	granulomatous mastitis	National University Hospital, Singapore	Not yet recruiting	No outcome recorded
Phase 4	NCT06999577 Comparator	Jun 2025 → May 2029 expected	gastroesophageal reflux disease, voice disorders	University of California, San Diego	Recruiting	No outcome recorded
Phase 4	NCT07312721 Background	Jan → Dec 2024	Helicobacter pylori infectious disease, chronic gastritis, peptic ulcer disease	Azfar Farogh	Completed	No outcome recorded
Phase 4	NCT07037888 Comparator	Dec 2023 → Sep 2026 expected	—	Henry Ford Health System	Recruiting	No outcome recorded
Phase 4	NCT05664685 Comparator	Oct 2022 → Oct 2023	Helicobacter pylori infectious disease	Pontificia Universidad Catolica de Chile	Completed	No outcome recorded
Phase 4	NCT04990804 Background	Aug 2021 → Feb 2022	spinal cord disorder, substance-related disorder	Vanderbilt University Medical Center	Terminated	No outcome recorded
Phase 4	NCT04901663 Comparator	Jun → Aug 2021	Helicobacter pylori infectious disease	Dow University of Health Sciences	Completed	No outcome recorded
Phase 4	NCT04766996 Background	May → Dec 2021	substance-related disorder	Emory University	Terminated	No outcome recorded
Phase 4	NCT06315478 Comparator	Feb → Mar 2021	Helicobacter pylori infectious disease	Helwan University	Completed	No outcome recorded
Phase 4	NCT04660123 Background	Dec 2020 → Dec 2021	Helicobacter pylori infectious disease, gastric cancer	Xijing Hospital of Digestive Diseases	Completed	No outcome recorded
Phase 4	NCT05342532 Comparator	Jun 2019 → Jan 2022	Helicobacter pylori infectious disease	Icahn School of Medicine at Mount Sinai	Completed	No outcome recorded
Phase 4	NCT04028466 Comparator	May 2019 → Mar 2020	gastroesophageal reflux disease	St. Luke's Medical Center, Philippines	Terminated	No outcome recorded
Phase 4	NCT03908619 Comparator	Apr 2019 → Mar 2021	Helicobacter pylori infectious disease	Changi General Hospital	Unknown	No outcome recorded
Phase 4	NCT03757650 Comparator	Oct 2018 → Nov 2020	Helicobacter pylori infectious disease, morbid obesity	Fatih Sultan Mehmet Training and Research Hospital	Completed	No outcome recorded
Phase 4	NCT03094416 Background	Jul 2018 → Jun 2020	postsurgical hypothyroidism	IBSA Institut Biochimique SA	Completed	No outcome recorded
Phase 4	NCT03327051 Comparator	Mar → Dec 2018	—	Stanford University	Completed	No outcome recorded
Phase 4	NCT02724150 Comparator	Dec 2017 → Feb 2021	peptic ulcer disease	Damascus Hospital	Withdrawn	No outcome recorded
Phase 4	NCT03238534 Comparator	Sep 2017 → Sep 2021	gastroesophageal reflux disease	Aboca	Completed	No outcome recorded
Phase 4	NCT04617613 Comparator	Sep 2016 → Sep 2018	Helicobacter pylori infectious disease	Al-Azhar University	Completed	No outcome recorded
Phase 4	NCT02711176 Comparator	Sep 2016 → Mar 2017	Helicobacter pylori infectious disease	Zahra Vahdat Shariatpanahi	Completed	No outcome recorded
Phase 4	NCT02986334 Comparator	Aug 2016 → Jun 2018	chronic pain syndrome	Apkar Apkarian	Completed	No outcome recorded
Phase 4	NCT02530879 Comparator	May 2016 → Aug 2017	upper respiratory tract disorder	Temple University	Withdrawn	No outcome recorded
Phase 4	NCT03444831 Background	Mar 2016 → Mar 2017	dyspepsia	Isfahan University of Medical Sciences	Completed	No outcome recorded
Phase 4	NCT02552537 Comparator	Sep 2015 → Mar 2017	food allergy	University of Zurich	Completed	No outcome recorded
Phase 4	NCT02500641 Background	Aug 2015 → May 2017	gout	Menarini International Operations Luxembourg SA	Completed	No outcome recorded
Phase 4	NCT02505945 Comparator	Jun 2015 → Oct 2017	gastroesophageal reflux disease	Torax Medical Incorporated	Completed	No outcome recorded
Phase 4	NCT02153177 Comparator	Jan 2015 → Dec 2018	rotator cuff syndrome	University of Chicago	Withdrawn	No outcome recorded
Phase 4	NCT02013427 Comparator	Oct 2014 → May 2016	chronic pain syndrome	Northwestern University	Completed	No outcome recorded
Phase 4	NCT02028234 Comparator	Feb 2014 → Mar 2015	coronary artery disorder	University of Roma La Sapienza	Unknown	No outcome recorded
Phase 4	NCT01851863 Comparator	May 2013 → Jun 2014	depressive disorder, dyspepsia	RenJi Hospital	Completed	No outcome recorded
Phase 4	NCT01777854 Comparator	Jan 2013 → Jul 2015	upper respiratory tract disorder	Ascension Health	Terminated	No outcome recorded
Phase 4	NCT01016717 Comparator	Dec 2012	coronary artery disorder	Sheba Medical Center	Withdrawn	No outcome recorded
Phase 4	NCT03980496 Comparator	Sep 2010 → Jun 2013	—	Medical University of Bialystok	Completed	No outcome recorded
Phase 4	NCT01093755 Comparator	Mar 2010 → Nov 2014	Barrett esophagus	Mayo Clinic	Completed	No outcome recorded
Phase 4	NCT01822600 Background	Jan 2010 → Aug 2011	active peptic ulcer disease	National Cheng-Kung University Hospital	Completed	No outcome recorded
Phase 4	NCT02536989 Comparator	Mar 2009 → Jun 2012	hemorrhagic disease, peptic ulcer disease	Far Eastern Memorial Hospital	Completed	No outcome recorded
Phase 4	NCT00825630 Comparator	Nov 2008 → Nov 2009	Helicobacter pylori infectious disease	Meridian Bioscience, Inc.	Completed	No outcome recorded
Phase 4	NCT00537732 Comparator	Apr 2007 → Dec 2010	gastroesophageal reflux disease	Matthias Schwab	Terminated	No outcome recorded
Phase 4	NCT00557349 Comparator	Nov 2006 → Nov 2007	ulcer disease	University of Missouri-Columbia	Completed	No outcome recorded
Phase 4	NCT00838682 Comparator	Apr 2006 → Jan 2009	peptic ulcer disease	The Catholic University of Korea	Terminated	No outcome recorded
Phase 4	NCT00141102 Comparator	Oct 2005 → May 2009	osteoarthritis, rheumatoid arthritis	Viatris Inc.	Completed	No outcome recorded
Phase 4	NCT00247130 Comparator	Oct 2005 → Jul 2007	active peptic ulcer disease	Keio University	Withdrawn	No outcome recorded
Phase 4	NCT00272467 Comparator	Jul 2005 → Apr 2008	gastric ulcer	Korea Otsuka International Asia Arab	Completed	No outcome recorded
Phase 4	NCT00164112 Background	Nov 2004 → Jun 2005	—	Bassett Healthcare	Completed	No outcome recorded
Phase 4	NCT00640809 Comparator	Oct 2003 → Apr 2004	inflammatory bowel disease	Viatris Inc.	Completed	No outcome recorded
Phase 4	NCT00854451 Comparator	Aug 1996 → Dec 1997	Helicobacter pylori infectious disease, duodenal ulcer	National Taiwan University Hospital	Completed	No outcome recorded

Phase not applicable23 trials
—	NCT07654049 Comparator	Jun 2026 → Jun 2027 expected	digestive system disorder	Second Affiliated Hospital, School of Medicine, Zhejiang University	Not yet recruiting	No outcome recorded
—	NCT07142486 Comparator	Sep 2025 → Jun 2026	digestive system disorder	McGill University	Completed	No outcome recorded
—	NCT07086937 Background	Jan → Jun 2025	Helicobacter pylori infectious disease	Muhammad Aamir Latif	Completed	No outcome recorded
—	NCT06566794 Comparator	Aug 2024 → Jan 2025	—	Helsinki University Central Hospital	Completed	No outcome recorded
—	NCT06114836 Comparator	Mar 2024 → Nov 2028 expected	gastroesophageal reflux disease	Nationwide Children's Hospital	Recruiting	No outcome recorded
—	NCT05517928 Background	Mar 2023 → Dec 2026 expected	—	Mayo Clinic	Recruiting	No outcome recorded
—	NCT05753774 Comparator	Aug 2022 → Aug 2026 overdue	—	Biao Zou	Recruiting	No outcome recorded
—	NCT05480241 Comparator	May 2022 → Dec 2023	acute pancreatitis, exocrine pancreatic insufficiency	Unidade Local de Saúde de Coimbra, EPE	Unknown	No outcome recorded
—	NCT04721704 Background	Sep 2020 → Sep 2022	bacterial gastritis	Shaheed Zulfiqar Ali Bhutto Medical University	Unknown	No outcome recorded
—	NCT03647852 Background	Sep 2019 → Feb 2026 overdue	immunoglobulin A vasculitis	Children's Hospital of Fudan University	Recruiting	No outcome recorded
—	NCT04130659 Comparator	Aug 2019 → Dec 2024	gastroesophageal reflux disease	Nekkar Lab Srl	Unknown	No outcome recorded
—	NCT05395949 Background	Jan 2019 → Dec 2022 overdue	breast disorder, granulomatous mastitis, psychiatric disorder	Wuhan University	Enrolling by invitation	No outcome recorded
—	NCT03793556 Comparator	May 2017 → Sep 2018	gastroesophageal reflux disease	SOFAR S.p.A.	Completed	No outcome recorded
—	NCT03388463 Comparator	May 2016 → Aug 2017	—	Menoufia University	Completed	No outcome recorded
—	NCT02685150 Background	Jan 2016 → Jun 2018	bile reflux, dyspepsia, gastroesophageal reflux disease	Chinese PLA General Hospital	Completed	No outcome recorded
—	NCT02515526 Comparator	Jun → Aug 2015	—	University of Cologne	Completed	No outcome recorded
—	NCT02108704 Comparator	Dec 2013 → Dec 2015	Helicobacter pylori infectious disease, Parkinson disease	University of Malaya	Completed	No outcome recorded
—	NCT01643785 Background	Jun 2012 → Jun 2013	Helicobacter pylori infectious disease	Chuncheon Sacred Heart Hospital	Terminated	No outcome recorded
—	NCT01593592 Background	Jun 2012 → Jan 2013	Helicobacter pylori infectious disease	Zagazig University	Completed	No outcome recorded
—	NCT03165253 Background	Jun 2011 → Jun 2012	Helicobacter pylori infectious disease	Bulent Ecevit University	Completed	No outcome recorded
—	NCT00981929 Comparator	Sep → Dec 2009	—	University of Southern Denmark	Terminated	No outcome recorded
—	NCT00772837 Background	Aug 2006 → Dec 2008	Helicobacter pylori infectious disease, dyspepsia	Aga Khan University	Completed	No outcome recorded
—	NCT01507792 Background	Jan 2002 → Jan 2011	bronchial disorder, disorder of iron metabolism and transport, laryngeal disorder	University of Turin, Italy	Completed	No outcome recorded

Press releases naming this drug 1 release

Date	Issuer	Release
2010-01-07	Teva Branded Pharmaceutical Products R&D, Inc.	Teva Announces Settlement Agreements With AstraZeneca Regarding Generic Prilosec® and Nexium® tevapharm.com ↗

Evidence & citations 18 cited values

Every value below carries the sentence it was read from. 501 sources stand behind the page.

Field	Value	Cited text
Known as	omeprazole	“After successful hemostasis, patients with high-risk PU bleeding (Forrest class Ia/Ib, IIa/IIb) were randomized into 1:1 to receive vonoprazan (20 mg twice a day for 3 days,...” PMID 38582271 ↗ Apr 2024 492 “We administered the Basel phenotyping cocktail (caffeine, efavirenz, flurbiprofen, omeprazole, metoprolol, midazolam) to patients with liver cirrhosis (n = 16 Child A, n = 15...” PMID 37328712 ↗ Jun 2023 “Ten healthy Caucasian subjects were orally dosed with the CIME combination (caffeine-CYP1A2, repaglinide-CYP2C8, tolbutamide-CYP2C9, omeprazole-CYP2C19,...” PMID 25465228 ↗ Dec 2014 “Nirogacestat 100 mg BID will be administered orally from Day 1 through Day 17 and an oral dose of CYP cocktail (CYP2B6 [bupropion 20 mg], CYP2C8 [repaglinide 0.05 mg], CYP2C9...” NCT07259330 ↗ “Two equally loaded capsules containing: Melatonin (2.0 mg) Nicotine (1.0 mg) Bupropion (37.5 mg) Repaglinide (0.25 mg) Losartan (12.5 mg) Omeprazole (10 mg) Chlorzoxazone...” NCT03563287 ↗ “A CYP probe cocktail composed of approved, commercially available drugs (caffeine, flurbiprofen, omeprazole, and midazolam) will be administered concomitantly as a single-dose...” NCT07426042 ↗ “BACKGROUND: Zegerid (on demand immediate-release omeprazole and sodium bicarbonate combination therapy) has demonstrated earlier absorption and more rapid pH change compared...” PMID 25706883 ↗ Feb 2015 “Allowable PPIs : Rabeprazole Sodium 20 mg QD, Esomeprazole Magnesium 20 mg or 40 mg QD, Lansoprazole 15 mg or 30 mg QD, Pantoprazole 20 mg or 40 mg QD, Omeprazole 20 mg or 40...” NCT00978016 ↗ “Ten volunteers received an oral cocktail capsule containing low doses of the probes bupropion (CYP2B6), flurbiprofen (CYP2C9), omeprazole (CYP2C19), dextromethorphan (CYP2D6),...” PMID 24722393 ↗ Apr 2014 “Group 1: (110) participants received reverse hybrid regimen in the form of clarithromycin 500mg bid, omeprazole 20 mg bid, amoxicillin 1gm bid, and metronidazole 500 mg tid for...” NCT04039412 ↗ “A Phase 1, Open-Label, Randomized, 3-Way Crossover Study to Evaluate the Relative Bioavailability of a Single Oral Dose of Aspirin Administered as PA32540 (Aspirin/Omeprazole)...” NCT00632086 ↗ “All participants were taking a standard dose QD PPI (dexlansoprazole, esomeprazole, esomeprazole magnesium, lansoprazole, omeprazole, pantoprazole, pantoprazole sodium...” NCT02637557 ↗ “Participants were randomized in a 3-way crossover design and received, in random order, Zegerid OTC Capsules (20 mg omeprazole and 1100 mg sodium bicarbonate), Prilosec OTC...” NCT01077076 ↗ “Dual therapy for 7 days: 40 mg omeprazole and 1g amoxicillin every 12h. After dual therapy continue with a quadruple therapy for 7 days: 40 mg omeprazole, 1g amoxicillin, 500...” NCT01464060 ↗ “12 grams of egg yolk powder containing about 2 grams of antibody twice a day for 2 weeks along with usual antibiotic treatment including OAC or omeprazole (40 mg/day),...” NCT06973889 ↗ “patients will receive LOAD therapy comprising of levofloxacin (250 mg with breakfast), omeprazole (40 mg before breakfast), nitazoxanide (Alina) (500 mg twice daily with meals)...” NCT06050824 ↗ “A single dose of selective substrates (probe drugs) was administered orally on days 15 and 30: caffeine (CYP1A2), tolbutamide (CYP2C9), omeprazole (CYP2C19), dextromethorphan...” PMID 37768317 ↗ Sep 2023 “Omeprazole 20 mg twice daily, in combination with bismuth subcitrate potassium (40 mg), metronidazole 125 mg and tetracycline 125 mg HCl. All patients must take 6 capsules of...” NCT00712413 ↗ “Participants will take a combination of 3 drugs (omeprazole 20 mg capsule, tolbutamide 500 mg tablet, and midazolam 2mg/mL liquid) orally (by mouth) or 2 tablets of study drug...” NCT01147887 ↗ “CYP substrates (Caffeine, Warfarin Sodium, Midazolam, Omeprazole, and Metoprolol Tartrate) will administered orally at Week 0 (Day 1) and Week 10 as per the commercially...” NCT04562116 ↗ “The control group will be treated with Omeprazole 20mg every 12 hours, Amoxicillin 1 gr every 12 hours, Clarithromycin 500 mg every 12 hours, Placebo identical to Bismuth...” NCT05664685 ↗ “The study will evaluate the pharmacokinetics (PK) and safety effects of co-administration of radiprodil with oral midazolam, rosuvastatin, warfarin, digoxin, and omeprazole in...” NCT06975605 ↗ “Effects of BMS-955176 on the Single-dose Pharmacokinetics of Probe Substrates (Caffeine, Metoprolol, Montelukast, Flurbiprofen, Omeprazole, Midazolam, Digoxin, and Pravastatin)...” NCT02578277 ↗ “Eradication group patients received oral omeprazole 20 mg, amoxicillin 1 g, and clarithromycin 500 mg twice daily for a week, whereas control group patients received no H...” PMID 29800546 ↗ May 2018 “Prednisone 30 mg/day, supplemented with calcium and omeprazole, and Prednisone were slowly reduced to 10 mg/day after symptoms were relieved, and combined with 7.5 mg/week MTX therapy.” NCT05395949 ↗ “Drug cocktail comprise of midazolam (2 mg), warfarin (10 mg), vitamin K (10 mg), omeprazole (40 mg), and fexofenadine (30 mg) will be administered on Study Day 1 and 43.” NCT02592317 ↗ “In standard triple therapy, children will be treated by Omeprazole(0.8-1.0mg/kg.d,bid), Amoxicillin (30-50mg/kg.d bid)and Clarithromycin (15-20mg/kg.d bid) for 10 days.” NCT02635191 ↗ “The intended dose is RHB-105 (12.5 mg rifabutin, 250 mg amoxicillin, and 10 mg omeprazole capsules) 4 capsules every eight hours, equivalent to a total daily dose of:” NCT01980095 ↗ “The triple regimen was defined as a combination of amoxicillin 1 gm twice a day, clarithromycin 500 mg twice a day and omeprazole is given in 40 mg twice a day dose.” NCT03968302 ↗ “probe drugs for simultaneous phenotyping of CYP1A2 (caffeine), CYP2B6 (efavirenz), CYP2C9 (losartan), 2C19 (omeprazole), CYP2D6 (metoprolol), and CYP3A4 (midazolam)” PMID 26123704 ↗ Jan 2016 “RHB-105 is an 'all-in-one' combination oral capsule consisting of combination therapy of Amoxicillin, Omeprazole and Rifabutin; as well as separate Riboflavin” NCT03198507 ↗ “Cocktail = Caffeine 200 mg, Metoprolol 50 mg, Montelukast 10 mg, Flurbiprofen 50 mg, Omeprazole 40 mg, Midazolam 5 mg, Digoxin 0.25 mg, and Pravastatin 40 mg” NCT02045966 ↗ “PPI-based triple therapy regimen consisted of (Omeprazole /pantoprazole 40mg) with amoxicillin (1000mg) and clarithromycin (500mg) twice daily for 14 days” NCT07275827 ↗ “ZYN002 (transdermal), midazolam (oral), omeprazole (oral), losartan (oral), dextromethorphan (oral), caffeine (oral), repaglinide (oral), bupropion (oral)” NCT06930872 ↗ “Subject will take a proton pump inhibitor (PPI) of their choice (Omeprazole, Esomeprazole, Pantoprazole, or Lansoprazole) 2 times a day for 8 weeks.” NCT02788591 ↗ “Day 1: Single oral dose of a cocktail of cytochrome P450 substrates (caffeine 100 mg, midazolam 2 mg, omeprazole 20 mg and metformin (transporter)” NCT05657613 ↗ “Oral drug cocktail consisting of caffeine (100 mg), dextromethorphan (30 mg), losartan (25 mg), midazolam syrup (2 mg), and omeprazole (20 mg).” NCT06693960 ↗ “The regimen consists of Omeprazole (20 mg/BD)+ Amoxicillin (1 g/day)+ Bismuth subcitrate (240 mg/BD)+ Azithromycin (500 mg/BD)for two weeks” NCT01759628 ↗ “The regimen consists of Omeprazole (20 mg/BD)+ Amoxicillin (1 g/day)+ Bismuth subcitrate (240 mg/BD)+ Azithromycin (500 mg/BD)for two weeks” NCT01712711 ↗ “Patient receive Omeprazole plus amoxicillin during 5 days and then omeprazole plus clarithromycin and metronidazole during another 5 days” NCT02395458 ↗ “followed by 5 days of omeprazole (20 mg/12 h), clarithromycin (500 mg/12 h) and metronidazole (500 mg/12 h)), or concomitant treatment” PMID 23665990 ↗ May 2013 “probe drugs will be oral midazolam (3 mg), warfarin (10 mg), omeprazole (40 mg), caffeine (200 mg), and dextromethorphan (30 mg).” NCT00401583 ↗ “Single oral administration of caffeine (100mg), omeprazole (20mg), losartan (25mg), dextromethorphan (30mg), and midazolam (1mg)” NCT04201197 ↗ “The Geneva cocktail is composed of caffeine, bupropion, flurbiprofen, omeprazole, dextromethorphan, midazolam, and fexofenadine.” PMID 32851583 ↗ Nov 2020 “Single administration on Day 13 of cocktail of CYP450 substrates: warfarin tablet, omeprazole capsule and caffeine oral solution” NCT02623296 ↗ “Repaglinide 0.25 mg, caffeine 100 mg, warfarin 10 mg (with vitamin K), omeprazole 40 mg, dextromethorphan 30 mg, midazolam 2 mg” NCT04233437 ↗ “Drug cocktail consists of caffeine, warfarin plus vitamin K, omeprazole, dextromethorphan, and midazolam, administered orally” NCT03718884 ↗ “Drug cocktail (caffeine, warfarin + vitamin K, omeprazole, dextromethorphan, midazolam) orally once daily, day 1 and day 20” NCT01001299 ↗ “modified "karolinska cocktail" (dextromethorphan, caffeine, losartan, omeprazole and paracetamol) before bariatric surgery” NCT01086722 ↗ “Patients will be treated concomitantly with omeprazole 20mg once in the evening before FMT and daily for the next 2 days.” NCT03167398 ↗ “Pancreatic Enzyme Replacement Therapy (PERT) 50000 Ph.U./meal + 25000 Ph.U./snack + Omeprazole 20mg once daily on fasting” NCT05480241 ↗ “Patients with H.pylori infection will take one tablet of 30 mg a day of Omeprazole for 14 days orally in the morning” NCT00825630 ↗ “Regimen 1 (R1): Clarithromycin 500mg BD, plus metronidazole 400mg TDS for 14days and Omeprazole 40mg BD for 6 weeks.” NCT07021729 ↗ “Zegerid (20 mg omeprazole/ 1100 mg sodium bicarbonate) taken with approximately 2 oz of water once daily for 7 days.” NCT01005719 ↗ “Proton pump inhibitor (eg, omeprazole 20 mg BID), Clarithromycin 500 mg BID, metronidazole 500 mg BID for 14 days” NCT03347513 ↗ “Bismuth 524mg QID, Metronidazole 500mg QID, Tetracycline 500MG QID, and Omeprazole 20 mg QID for 14 days.” NCT07104318 ↗ “Omeprazole 20 mg or Rabeprazole 10 mg bid + clarithromycin 500 mg and amoxicillin 1,000 mg bid for 7 days” NCT01002443 ↗ “Famotidine (20mg BID) or Omeprazole (20mg daily) will be prescribed along with NSAIDS for GI prophylaxis” NCT04990804 ↗ “oral dose of the Cooperstown Cocktail (midazolam, omeprazole, warfarin, caffeine, and dextromethorphan)” NCT02434861 ↗ “Omeprazole (20 mg/BD)+ Amoxicillin (1 g/day)+ Bismuth subcitrate (240 mg/BD)+ Azithromycin (500 mg/BD)” NCT01654549 ↗ “ten days of standard triple region (20mg omeprazole 20mg, 1.0 amoxicillin, 0.5 clarithromycin, Bid).” NCT02803216 ↗ “GT08 is the combination of omeprazole 40mg daily, lauric acid 150-300mg daily, NAC 1.2 - 2g daily” NCT01109381 ↗ “PA32540 tablets contain 325 mg enteric coated (EC) aspirin and 40 mg immediate-release omeprazole” NCT00960869 ↗ “PA32540 tablets contain 325 mg enteric coated (EC) aspirin and 40 mg immediate-release omeprazole” NCT00961350 ↗ “Suggested medications included ranitidine 150 mg PC BID or omeprazole 20 mg PO QD or equivalent.” NCT01042704 ↗ “PPI(pantoprazole 40mg, lansoprazole 30mg, esomeprazole 40mg, rabeprazole 20mg, omeprazole 20mg)” NCT01643785 ↗ “omeprazole 2x1) + clarithromycin 2x500 mg + amoxicilline 2x1000 mg + Bismuth Subsalicylate 2x1” NCT03757650 ↗ “Omeprazole, 20mg, amoxicillin, 1000mg, and clarithromycin, 500mg, all twice a day for 2 weeks.” NCT01133951 ↗ “Omeprazole 20mg, lansoprazole 30mg, pantoprazole 40mg, alprazole 5mg, any one of these.” NCT04660123 ↗ “BGB-3111 and Drug Cocktail (midazolam, warfarin, omeprazole, digoxin and rosuvastatin)” NCT03561298 ↗ “GBT440 capsules followed by Caffeine, S-warfarin+vitamin K, Omeprazole, and Midazolam” NCT02567682 ↗ “PPIs (omeprazole, lansoprazole, etc, as not specified) for prevention of peptic ulcer” NCT02288078 ↗ “Omeprazole (40 mg orally) with collection of a plasma sample 2 hours after dosing.” NCT00164112 ↗ “omeprazole, esomeprazole, lansoprazole, dexlansoprazole, pantoprazole, rabeprazole” NCT03094416 ↗ “Omeprazole 40 mg BID, Amoxicillin 1 g BID, Clarithromycin 500 mg BID for 14 days.” NCT07312721 ↗ “For IM and PM, in this study, patients selected the standard dose of Omeprazole.” NCT02689583 ↗ “Session 1: CYP2C19 phenotyping following a single 10 mg oral dose of omeprazole.” NCT07014930 ↗ “Caffeine + Warfarin (plus vitamin K) + Omeprazole + Dextromethorphan + Midazolam” NCT02993471 ↗ “Omeprazole, Amoxicillin, Metronodazole and TRITEC (ranitidine bismuth citrate)” NCT02004197 ↗ “Buspirone 5mg used QID a day after meal plus 20mg omeprazole before breakfast.” NCT03444831 ↗ “PA32540 (enteric-coated aspirin 325 mg and immediate-release omeprazole 40 mg)” PMID 26725920 ↗ Apr 2016 “proton pump inhibitor-based triple therapy omeprazole /pantoprazole (40 mg)” NCT07293910 ↗ “Amoxycillin 1gm twice a day (BD) Clarithromycin 500mg BD Omeprazole 20mg BD” NCT02108704 ↗ “Omeprazole 1 mg/ kg and continuing nutrition containing cow's milk protein” NCT06255886 ↗ “Omeprazole 30mg twice Clarithromycin 500mg twice Amoxicillin 1000mg twice” NCT01938534 ↗ “500 mg tolbutamide, 40 mg omeprazole, and 30 mg dextromethorphan orally.” NCT02819102 ↗ “Use of Omeprazole, Esomeprazole, Lansoprazole, Pantoprazole, Rabeprazole” NCT07611162 ↗ “includes midazolam, caffeine, losartan, omeprazole, and dextromethorphan” NCT03505853 ↗ “Including the Omeprazole 40 or 80 mg, Clarithromycin and Amoxicillin.” NCT02922699 ↗ “1. Omeprazole 0.8mg/kg.d.The maximum dose is less than 40mg per day” NCT03647852 ↗ “caffeine, dextromethorphan, flurbiprofen, midazolam, and omeprazole” NCT03720366 ↗ “Oral dose of omeprazole, voriconazole, itraconazole, or rifampicin” NCT05822544 ↗ “Immediate release omeprazole 40 mg and sodium bicarbonate 1,100 mg” NCT02710994 ↗ “Zegerid 20mg capsule (20mg omeprazole and 1100mg sodium carbonate” NCT01710995 ↗ “10mg omeprazole and 10mg sham ,once a day,all for 4 weeks.” NCT02892357 ↗ “dextromethorphan, caffeine, omeprazole, and midazolam” NCT05334108 ↗ “1600 mg GS-9973 (Formulation 1) plus 20 mg omeprazole” NCT01841489 ↗ “CYP2C19 (omeprazole 20 mg), CYP2D6 (metoprolol 50 mg)” PMID 39707077 ↗ Dec 2024 “Proton pump inhibitor = omeprazole 20 mg twice daily” NCT01507792 ↗ “CGT 2168 (clopidogrel, 75 mg and omeprazole, 20 mg)” NCT00620802 ↗ “1. Omeprazole (or esomeprazole): 20mg, 2 times/day” NCT06943794 ↗ “Omeprazole-magnesium 20.6 mg, tablet, single dose” NCT00808769 ↗ “Omeprazole hard capsule for oral administration.” NCT05123820 ↗ “omeprazole 40 mg once per day for one month.” NCT03428568 ↗ “Children were given omeprazole for 14 days.” NCT07086937 ↗ “Omeprazole tablets for oral use, 40 mg/day” NCT03195946 ↗ “Omeprazole, amoxycillin, clarithromycin” NCT03491995 ↗ “Omeprazole+Amoxicillin+Clarithromycin” NCT03365609 ↗ “* omeprazole: two 20 mg oral tablets” NCT04764851 ↗ “A capsule of omeprazole ABBOTT® 10mg” NCT02590185 ↗ “lansoprazole/omeprazole combination” NCT01129713 ↗ “Omeprazole 20 mg orally twice daily” NCT01723059 ↗ “PPI alone (generic omeprazole)” NCT04130659 ↗ “PN 200 (Omeprazole/Naproxen)” NCT00442208 ↗ “Group O (omeprazole 20 mg)” NCT02703896 ↗ “20 mg omeprazole (CYP2C19)” PMID 31099895 ↗ Jul 2019 “indometacin (+Omeprazole)” NCT01146197 ↗ “CYP2C19 Omeprazole 10 mg” NCT04814498 ↗ “Omeprazole (Prilosec)” NCT02039869 ↗ “Omeprazole (20 mg)” NCT00741468 ↗ “Drug: Omeprazole” NCT05624229 ↗ “Drug: Omeprazole” NCT03662269 ↗ “Drug: Omeprazole” NCT01636557 ↗ “Omeprazole 20mg” NCT02056743 ↗ “Omeprazole” NCT00857597 ↗ NCT03716427 ↗ NCT06162169 ↗ NCT01129375 ↗ NCT01129388 ↗ NCT00446004 ↗ NCT01129414 ↗ NCT00426595 ↗ NCT02249871 ↗ NCT02684799 ↗ NCT02685150 ↗ NCT02685436 ↗ NCT00492622 ↗ NCT04198948 ↗ NCT03378960 ↗ NCT06031454 ↗ NCT02524210 ↗ NCT07235748 ↗ NCT03205228 ↗ NCT02552537 ↗ NCT01657578 ↗ NCT02249936 ↗ NCT05392127 ↗ NCT00964106 ↗ NCT04170270 ↗ NCT02365558 ↗ NCT00903448 ↗ NCT00001191 ↗ NCT00542347 ↗ NCT01458054 ↗ NCT00692510 ↗ NCT00164866 ↗ NCT05981365 ↗ NCT07700953 ↗ NCT00164931 ↗ NCT00420615 ↗ NCT00854451 ↗ NCT00001337 ↗ NCT03547024 ↗ NCT01465113 ↗ NCT05134350 ↗ NCT00327132 ↗ NCT02844621 ↗ NCT01777854 ↗ NCT00141102 ↗ NCT01218620 ↗ NCT03358706 ↗ NCT03781596 ↗ NCT04199624 ↗ NCT01694706 ↗ NCT01911728 ↗ NCT02345304 ↗ NCT04876807 ↗ NCT03551691 ↗ NCT02500641 ↗ NCT01093755 ↗ NCT03291249 ↗ NCT05264142 ↗ NCT04721704 ↗ NCT04617613 ↗ NCT06539494 ↗ NCT00537732 ↗ NCT05651074 ↗ NCT05609929 ↗ NCT02229877 ↗ NCT01735227 ↗ NCT05863858 ↗ NCT02647086 ↗ NCT06943482 ↗ NCT01150162 ↗ NCT05753774 ↗ NCT00641264 ↗ NCT01557335 ↗ NCT06150898 ↗ NCT03531762 ↗ NCT00668317 ↗ NCT00256737 ↗ NCT01813552 ↗ NCT01170533 ↗ NCT00818870 ↗ NCT01275170 ↗ NCT04525664 ↗ NCT00655746 ↗ NCT00674115 ↗ NCT04394663 ↗ NCT06494761 ↗ NCT05497557 ↗ NCT06822166 ↗ NCT03980496 ↗ NCT02609386 ↗ NCT01016717 ↗ NCT02397382 ↗ NCT05438303 ↗ NCT01269788 ↗ NCT00519519 ↗ NCT00402259 ↗ NCT07223671 ↗ NCT01766050 ↗ NCT03058419 ↗ NCT03979989 ↗ NCT03556592 ↗ NCT02085018 ↗ NCT05444556 ↗ NCT07142486 ↗ NCT01415128 ↗ NCT02518373 ↗ NCT01599858 ↗ NCT01762644 ↗ NCT03388463 ↗ NCT01901276 ↗ NCT06917963 ↗ NCT05799105 ↗ NCT03936374 ↗ NCT01470690 ↗ NCT02950259 ↗ NCT01587885 ↗ NCT06686628 ↗ NCT01392755 ↗ NCT02243553 ↗ NCT00367211 ↗ NCT02190708 ↗ NCT00259051 ↗ NCT00298779 ↗ NCT05338502 ↗ NCT00374101 ↗ NCT01415349 ↗ NCT01287195 ↗ NCT01147588 ↗ NCT00861640 ↗ NCT02299687 ↗ NCT06215430 ↗ NCT01187862 ↗ NCT06566794 ↗ NCT07487142 ↗ NCT02438072 ↗ NCT02140073 ↗ NCT00942136 ↗ NCT03650543 ↗ NCT00981929 ↗ NCT00045799 ↗ NCT00719420 ↗ NCT02595372 ↗ NCT03059303 ↗ NCT03033342 ↗ NCT00003617 ↗ NCT01458990 ↗ NCT06605950 ↗ NCT05646862 ↗ NCT07654049 ↗ NCT01570569 ↗ NCT02957474 ↗ NCT00765206 ↗ NCT02492776 ↗ NCT07007806 ↗ NCT03530995 ↗ NCT03302845 ↗ NCT02256813 ↗ NCT00838682 ↗ NCT03028103 ↗ NCT02638116 ↗ NCT04337580 ↗ NCT04108676 ↗ NCT04959266 ↗ NCT00664209 ↗ NCT03457727 ↗ NCT03457597 ↗ NCT02453022 ↗ NCT05517928 ↗ NCT01269333 ↗ NCT03165253 ↗ NCT03561233 ↗ NCT00633932 ↗ NCT04676035 ↗ NCT03362268 ↗ NCT01925144 ↗ NCT07565441 ↗ NCT05342532 ↗ NCT02586636 ↗ NCT00290823 ↗ NCT05468164 ↗ NCT01539655 ↗ NCT01335334 ↗ NCT03864042 ↗ NCT04425902 ↗ NCT03362281 ↗ NCT01323465 ↗ NCT01896557 ↗ NCT02182336 ↗ NCT01678053 ↗ NCT02505945 ↗ NCT04128787 ↗ NCT02530879 ↗ NCT00634114 ↗ NCT06861478 ↗ NCT01408849 ↗ NCT01593592 ↗ NCT04246762 ↗ NCT02515526 ↗ NCT02394340 ↗ NCT07269756 ↗ NCT04028466 ↗ NCT00247130 ↗ NCT06690164 ↗ NCT05635110 ↗ NCT07149415 ↗ NCT01338077 ↗ NCT02016820 ↗ NCT00475527 ↗ NCT05599828 ↗ NCT02762123 ↗ NCT02262169 ↗ NCT02422706 ↗ NCT01824199 ↗ NCT05109390 ↗ NCT02407119 ↗ NCT07214662 ↗ NCT00817245 ↗ NCT00259077 ↗ NCT01786382 ↗ NCT04154748 ↗ NCT04130659 ↗ NCT05273775 ↗ NCT06383338 ↗ NCT01596647 ↗ NCT03793556 ↗ NCT01159145 ↗ NCT05067439 ↗ NCT00357240 ↗ NCT02433457 ↗ NCT02153177 ↗ NCT05254548 ↗ NCT01489943 ↗ NCT06719622 ↗ NCT01934569 ↗ NCT07156201 ↗ NCT03709355 ↗ NCT00989300 ↗ NCT07665723 ↗ NCT01499368 ↗ NCT04069286 ↗ NCT00441519 ↗ NCT02253875 ↗ NCT02536989 ↗ NCT02254148 ↗ NCT06510010 ↗ NCT06948006 ↗ NCT00953381 ↗ NCT06393868 ↗ NCT03086070 ↗ NCT03234699 ↗ NCT05433896 ↗ NCT06562907 ↗ NCT06279234 ↗ NCT03333824 ↗ NCT01822977 ↗ NCT03367195 ↗ NCT05487235 ↗ NCT01452906 ↗ NCT04368585 ↗ NCT00226044 ↗ NCT06145217 ↗ NCT00002682 ↗ NCT04672018 ↗ NCT06322706 ↗ NCT03866434 ↗ NCT05581992 ↗ NCT02724150 ↗ NCT01287598 ↗ NCT01337804 ↗ NCT02013453 ↗ NCT01061034 ↗ NCT00442052 ↗ NCT02760615 ↗ NCT05932277 ↗ NCT00364481 ↗ NCT01517399 ↗ NCT05041920 ↗ NCT00339768 ↗ NCT00559364 ↗ NCT01122160 ↗ NCT01001247 ↗ NCT00640809 ↗ NCT06093945 ↗ NCT00210470 ↗ NCT01361217 ↗ NCT00726726 ↗ NCT00952978 ↗ NCT01000818 ↗ NCT00669955 ↗ NCT02220777 ↗ NCT01851863 ↗ NCT04333407 ↗ NCT00559182 ↗ NCT04643249 ↗ NCT03238534 ↗ NCT03363815 ↗ NCT05891119 ↗ NCT07068841 ↗ NCT05319899 ↗ NCT03131973 ↗ NCT01000220 ↗ NCT05319912 ↗ NCT01983566 ↗ NCT02730026 ↗ NCT04149470 ↗ NCT00931073 ↗ NCT07037888 ↗ NCT02772601 ↗ NCT03327051 ↗ NCT01782560 ↗ NCT02013427 ↗ NCT02893709 ↗ NCT04989829 ↗ NCT02028234 ↗ NCT01795794 ↗ NCT07040839 ↗ NCT01136317 ↗ NCT02391688 ↗ NCT03908619 ↗ NCT02226783 ↗ NCT03267680 ↗ NCT00930670 ↗ NCT03146325 ↗ NCT06315478 ↗ NCT05852769 ↗ NCT00272467 ↗ NCT06114836 ↗ NCT00971581 ↗ NCT02623816 ↗ NCT00003151 ↗ NCT01303445 ↗ NCT04840888 ↗ NCT00557921 ↗ NCT01661101 ↗ NCT00772837 ↗ NCT02123498 ↗ NCT04914936 ↗ NCT01876108 ↗ NCT04930991 ↗ NCT06999577 ↗ NCT00443170 ↗ NCT01822600 ↗ NCT00251030 ↗ NCT02224053 ↗ NCT02272868 ↗ NCT03100838 ↗ NCT04901663 ↗ NCT00942175 ↗ NCT02584751 ↗ NCT02986334 ↗ NCT01566474 ↗ NCT05680870 ↗ NCT02473627 ↗ NCT00442741 ↗ NCT00582972 ↗ NCT01341600 ↗ NCT02790840 ↗ NCT00404534 ↗ NCT00557349 ↗ NCT00930306 ↗ NCT02621359 ↗ NCT00950339 ↗ NCT02740712 ↗ NCT01711320 ↗ NCT02472600 ↗ NCT01462318 ↗ NCT05741385 ↗ NCT02783040 ↗ NCT06378398 ↗
Known as	ABBOTT	“A capsule of omeprazole ABBOTT® 10mg” NCT02590185 ↗
Known as	Antra MUPS	ClinicalTrials.gov intervention name — accepted as the source's own label NCT04679948 ↗
Known as	Lansomeprazole	“Lansomeprazole” NCT00857597 ↗
Known as	Lanzol	ClinicalTrials.gov intervention name — accepted as the source's own label NCT02711176 ↗
Known as	Losec	“BACKGROUND: Zegerid (on demand immediate-release omeprazole and sodium bicarbonate combination therapy) has demonstrated earlier absorption and more rapid pH change compared...” PMID 25706883 ↗ Feb 2015 3 “Losec 20mg capsule (20mg omeprazole)” NCT01710995 ↗ “1. Brand name: Losec® Cap.” NCT00272467 ↗ NCT03105375 ↗
Known as	OME	“Omeprazole (OME) is the most frequently used proton pump inhibitor.” NCT01470690 ↗
Known as	Omeprazole (Prilosec)	“Omeprazole (Prilosec)” NCT02039869 ↗
Known as	omeprazole-magnesium	“Prilosec OTC (omeprazole-magnesium 20.6 mg) tablet to be taken with a glass of water prior to breakfast” NCT00903448 ↗
Known as	OMP	“VECAM is a combination of omeprazole (OMP) and SA.” PMID 22372795 ↗ Feb 2012 1 “Oral Omeprazole (OMP)” NCT02433457 ↗
Known as	Prilosec	“This study is designed to evaluate the potential for an effect of Ritonavir (Norvir®) or omeprazole (Prilosec®) on the pharmacokinetics of samatasvir and to assess the safety...” NCT01813552 ↗ 7 “Prilosec (omeprazole) 40 mg delayed-release capsule is opaque, hard gelatin, apricot, and amethyst colored capsules, coded 743 on cap and PRILOSEC 40 on the body for oral...” NCT02453022 ↗ “This study will attempt to determine the effectiveness of Omeprazole (Prilosec) in the treatment of patients with Zollinger-Ellison Syndrome.” NCT00001191 ↗ “complete a 14-day course of omeprazole (Prilosec®), and then complete a follow-up blood and stool sample.” NCT02844621 ↗ “one EC omeprazole (Prilosec®) 40 mg capsule” NCT01557335 ↗ “Prilosec” NCT02794844 ↗ NCT04766996 ↗ NCT02504554 ↗
Known as	Prilosec (Omeprazole)	“Prilosec (Omeprazole)” NCT02153177 ↗
Known as	Prilosec OTC	“Prilosec OTC (omeprazole-magnesium 20.6 mg) tablet to be taken with a glass of water prior to breakfast” NCT00903448 ↗
Known as	Zegerid	ClinicalTrials.gov intervention name — accepted as the source's own label NCT01129778 ↗
Action	Inhibit	“the oral gastric acid antisecretory drug, Omeprazole, which functions as a H+ - K+ ATPase inhibitor.” NCT00001191 ↗
Modality	Other / unclassified	“Omeprazole is a proton pump inhibitor” PMID 32594305 ↗ Oct 2020
Route	Oral	“oral Omeprazole” NCT00001191 ↗
Target	CYP2C19	“CYP2C19 inhibition by omeprazole” NCT01269333 ↗